Hepatic arterial infusion of oxaliplatin plus raltitrexed in patients with intermediate and advanced stage hepatocellular carcinoma: A phase II, single-arm, prospective study

This publication has 24 references indexed in Scilit:

• Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
  JAMA Oncology, 2019
• Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis
  Cancer Chemotherapy and Pharmacology, 2018
• Hepatocellular carcinoma
  The Lancet, 2018
• Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
  The Lancet Oncology, 2009
• Management of Hepatocellular Carcinoma *
  Hepatology, 2005
• 5-Fluorouracil Pharmacokinetics: Causes for Variability and Strategies for Modulation in Cancer Chemotherapy
  Cancer Investigation, 1999
• Raltitrexed
  Drugs, 1998
• Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors.
  Journal of Clinical Oncology, 1996
• Optimal two-stage designs for phase II clinical trials
  Controlled Clinical Trials, 1989
• Experiments on the efficacy and toxicity of locoregional chemotherapy of liver tumors with 5-fluoro-2?-deoxyuridine (FUDR) and 5-fluorouracil (5-FU) in an animal model
  Journal of Cancer Research and Clinical Oncology, 1986